Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03711929) enrolled 145 participants across three groups during its first, double-masked phase: 57 received DE-109 injectable solution (the test treatment), 59 received a sham (dummy) procedure as a control, and 29 received DE-109 in a third "dummy arm." The trial was measuring eye inflammation — specifically a cloudiness inside the eye called "vitreous haze" — in people with a condition called uveitis (inflammation at the back of the eye). The main question the trial asked was: what proportion of treated eyes reached a vitreous haze score of zero (meaning no detectable inflammation) by the fifth month? The reported data shows that at month 5 — the primary measurement point — 15.7% of eyes in the main DE-109 group, 12.2% of eyes in the sham (control) group, and 28.7% of eyes in the dummy DE-109 arm reached a vitreous haze score of zero. At the earlier month 3 check, the reported figures were 14.7%, 5.5%, and 15.4% respectively. The trial also used a broader "composite score" (a scale from −1 to 3 that factored in improvement, worsening, and whether rescue treatments were needed). The reported data shows the average composite scores at month 3 were 0.4, 0.3, and 0.4 for the three groups, and at month 5 were 0.3, 0.3, and 0.6 respectively — all sitting near the lower end of that scale. These numbers are what was recorded and submitted; they do not on their own tell us whether any difference between the groups is meaningful, and no conclusions about why differences appeared between arms should be drawn from this summary alone. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37172783) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have active inflammation in the back part of your eye (called uveitis) that is not caused by an infection
Who may not be able to join:
- You are a woman who is currently pregnant, breastfeeding, or planning to become pregnant
- Your eye inflammation is caused by, or suspected to be caused by, an infection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Vitreous Haze (VH) of Zero Response at Month 5
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.